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Scleroderma fibroblasts exhibit numerous phenotypic
differences when compared with healthy skin fibroblasts.
Some of these differences, in particular overexpression
of collagen type I and other extracellular matrix proteins,
parallel the effect of transforming growth factor-b (TGF-
b) on dermal fibroblasts, suggesting that the scleroderma
fibroblast phenotype may result from activation of auto-
crine TGF-b signaling. To test this hypothesis we exam-
ined the role of TGF-b Type I and Type II receptors in
regulating collagen type I transcription. We have shown
that overexpression of either Type I or Type II receptors
significantly (3–4-fold) increases a2 (I) collagen promoter
activity in transient transfection assays in dermal
fibroblasts. Addition of anti-TGF-b antibody abolished,
whereas addition of plasmin enhanced, the stimulatory
Excessive extracellular matrix (ECM) deposition in skin,lung, or other organs is a hallmark of systemic sclerosis(SSc) (LeRoy, 1992). Whereas the pathogenesis of SSc isstill poorly understood, increasing evidence suggests thatactivation of lesional fibroblasts contributes to the fibrotic
process (Kulozik et al, 1990; Jelaska et al, 1996). Numerous pleiotropic
differences between cultured SSc and healthy skin fibroblasts that can
contribute to excessive ECM deposition in vivo have been documented.
These differences include: elevated expression of collagens type I, III,
VI, VII, and fibronectin (LeRoy, 1974; Buckingham et al, 1978;
Peltonen et al, 1990; Xu et al, 1991; Rudnicka et al, 1994); increased
synthesis of glycosaminoglycans (Falanga et al, 1987); elevated expression
of tissue inhibitor of metalloproteinase (TIMP-1) (Bou-Gharios et al,
1994; Kikuchi et al, 1995; Kirk et al, 1995); elevated expression of
intercellular adhesion molecule (Abraham et al, 1991); and elevated
expression of c-myc and c-myb protooncogenes (Trojanowska et al,
1988; Piccini et al, 1996). In addition, SSc fibroblasts constitutively
produce pro-IL-1a (Kawaguchi, 1994) and constitutively secrete IL-
6 (Feghali et al, 1994). SSc and healthy skin fibroblasts also differ in
their responses to transforming growth factor-β (TGF-β) and basic
fibroblast growth factor (bFGF). TGF-β stimulates platelet-derived
growth factor-α receptor expression in SSc fibroblasts, but not in
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effect of receptor overexpression on collagen promoter
activity, suggesting that this effect depends on autocrine
TGF-b. Moreover, these cotransfection experiments indi-
cated that expression levels of TGF-b receptors is a
limiting factor in the autocrine regulation of collagen
type I transcription by TGF-b. Comparison of the TGF-
b receptor Type I and Type II mRA expression levels
in scleroderma and normal fibroblasts have indicated
elevated expression (2-fold) of both receptor types in
scleroderma cells, which correlated with increased bind-
ing of TGF-b. Significantly, elevated TGF-b receptor
levels correlated with elevated a2 (I) collagen mRNA
levels. These results suggest that the elevated production
of collagen type I by scleroderma fibroblasts results from
overexpression of TGF-b receptors. Key words: collagen
type I/fibrosis. J Invest Dermatol 110:47–51, 1998
healthy skin fibroblasts (Yamakage et al, 1992). Conversely, bFGF
stimulates expression of platelet-derived growth factor-α receptors in
normal fibroblasts, but not in SSc fibroblasts (Kikuchi et al, 1992b;
Ichiki et al, 1995). In addition, SSc fibroblasts are less sensitive to the
stimulatory effects of cytokines that regulate collagen production such
as Oncostatin M, IL-4, and TGF-β (Duncan et al, 1995; Lee et al,
1996; Kikuchi et al, 1992a). SSc fibroblasts also abnormally regulate
collagen type I gene when placed into three-dimensional collagen gels
(Eckes et al, 1996).
The molecular mechanism underlying these diverse phenotypic
differences observed in SSc fibroblasts is presently unknown; however,
many of the characteristics of SSc fibroblasts parallel those of healthy
fibroblasts exposed to TGF-β (Massague, 1990), suggesting that the
SSc phenotype may be a result of activation of an autocrine TGF-β
loop. This study was undertaken to test this hypothesis. First we
investigated the role of autocrine TGF-β in regulating collagen type I
gene transcription by dermal fibroblasts. We then examined the
expression of TGF-β receptors in SSc and healthy controls and
correlated the level of such expression with collagen type I gene
expression by the same cells. The results of our studies are consistent
with the notion that elevated expression of TGF-β receptors by SSc
fibroblasts is responsible for the elevated expression of collagen type I
and possibly other phenotypic differences of SSc cells.
MATERIALS AND METHODS
Cell cultures Fibroblasts were obtained by skin biopsy from the affected
areas (dorsal forearm) of patients with diffuse cutaneous SSc with less than 2 y
of skin thickening. Control fibroblasts were obtained by skin biopsy of healthy
donors (within several days of SSc biopsy); these were matched with each SSc
patient for age, race, gender, and biopsy site and were processed in parallel.
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Primary explant cultures were established as described previously (Yamakage
et al, 1992). Fibroblasts between third and fifth subpassages were used for
experiments. Dermal skin fibroblasts derived from a 2-mo-old child (GM05756
A) were obtained from Coriell Cell Repositories (Camden, NJ).
Plasmids construction Generation of a –772 COL1 A2/CAT construct
consisting of the human collagen α2 (I) gene fragment (158 to –772 bp relative
to the transcription start site) linked to chloramphenicol acetyltransferase reporter
gene was previously described (Tamaki et al, 1995). pcDNA3.1 (Invitrogen,
San Diego, CA) was used to generate expression vectors for the TGF-β
receptors. The TGF-β-RI cDNA (kindly provided by Dr. ten Dijke, Ludwig
Institute for Cancer Research, Uppsala, Sweden) was amplified using the
polymerase chain reaction technique (primer 1, TAGAAGCTTGGCGAGGC-
GAGGTTTGC, primer 2, GACAAGCTTGACACAGAAGTGGCAC; both
primers included the HindIII site) and was subcloned into pcDNA3.1 linearized
with HindIII. The TGF-β-RII cDNA (kindly provided by Dr. Weinberg,
Whitehead Institute for Biomedical Research, Cambridge, MA) was excised
by EcoRI and subcloned on the EcoRI site of pcDNA3.1. The kinase deficient
TGF-β-RII (TGF-RII∆K) (kindly provided by Dr. Schneider, Molecular
Cardiology Unit, Baylor College of Medicine, Houston, TX) was excised with
HindIII and XbaI and subcloned on pcDNA3.1 digested with HindIII and
XbaI. Plasmids used in transient transfection assays were purified by a double
CsCl gradient.
Transient transfections and chloramphenicolacetyltransferase
assays For transient transfections human fibroblasts (GM05756 A) were grown
to 90% confluence in 100 mm dishes in Dulbecco’s modified Eagle’s medium
(DMEM) with 10% fetal bovine serum. Monolayers were washed and cells were
transfected by the calcium phosphate technique with 10 µg of –772 COL1 A2/
CAT and various pcDNA3.1 derivatives carrying TGF-β receptor clones as
described in the text. A dose response curve using pcDNA3.1 vector had been
constructed to establish the optimum amount of DNA for transfections, and
therefore 1.5 µg of all the pcDNA3.1 plasmid derivatives was used. A pSV-β-
galactosidase control vector (Promega, Madison, WI) (5 µg) was cotransfected to
normalize for transfection efficiency. β-galactosidase activity was measured using
the Galacto-LightTM chemiluminescent reporter assay system (Tropix, Bedford,
MA). After incubation overnight, the medium was replaced with DMEM con-
taining either 0.1% bovine serum albumin or 1% fetal bovine serum with or
without 2 ng recombinant TGF-β1 (UBI, Lake Placid, NY) per ml. Incubation
was then continued for 24 h. Cells were harvested in 0.25 M Tris-HCl, pH 8, and
fractured by freeze-thawing. Extracts were normalized for protein contents as
measured by Bio-Rad reagents and then incubated with butyryl-CoA and
[14C]chloramphenicol for 90 min at 37°C, an assay condition predetermined to
be within the linear range of chloramphenicol acetyltransferase activity for these
samples. Butyrated chloramphenicol was extracted using organic solvent (2:1
mixture of tetramethylpentadecane and xylene) and quantitated by scintillation
counting. Each experiment was performed in duplicate.
RNA preparation and northern blot analysis Fibroblasts were grown to
confluence in DMEM supplemented with 10% fetal bovine serum, and then
incubated for 48 h in serum-free medium (DMEM plus 0.1% bovine serum
albumin). Total RNA was extracted and analyzed by northern blot as described
previously (Yamakage et al, 1992). Filters were sequentially hybridized with
radioactive probes for TGF-β-RI, TGF-β-RII, proα2 (I) collagen, and GAPDH.
The filters were scanned with a phosphorimager scanner (Molecular Dynamics,
Sunnyvale, CA).
Display of TGF-b receptors by 125I-labeled TGF-b Confluent SSc and
healthy fibroblasts grown in 6 well plates were incubated for 3 h at 37°C in
phosphate-buffered saline to remove bound TGF-β. Next, cells were incubated
with 125I-TGF-β (100 pM) for 3 h at 4°C in binding buffer (25 mM HEPES,
3 mM phenylmethylsulfonyl fluoride, 1 mg soybean trypsin inhibitor per ml).
Unbound 125I-TGF-β was then washed off. Cross-linking was performed by
incubation with 30 mM disuccinimityl suberate for 30 min at 4°C in binding
buffer. Cells were then washed with 250 mM sucrose, 1 mM ethylenediamine
tetraacetic acid, 3 mM phenylmethylsulfonyl fluoride, and 1 mg per ml soybean
trypsin inhibitor. After medium removal cells were solubilized in 1% Triton X-
100, 3 mM phenylmethylsulfonyl fluoride, and 1 mg per ml soybean trypsin
inhibitor for 3 h at room temperature. Cell lysates were centrifuged at 12,000
g for 20 min. Supernatants were collected and protein concentration was
measured. Equal amounts of proteins were electrophoresed through 3–12%
gradient sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visual-
ized by autoradiography.
RESULTS
Collagen type I transcription is under autocrine control by
TGF-b in human dermal fibroblasts Expression vectors carrying
Figure 1. Overexpression of TGF-β type I and type II receptors activates
collagen promoter activity in human dermal fibroblasts. Human dermal
fibroblasts were transiently cotransfected with 10 µg of α2 (I) collagen promoter/
CAT reporter gene construct and with either 3 µg of the pcDNA3.1 vector
(control) or 1.5 µg of pcDNA3.1 carrying wild-type cDNA for the TGF-β
type I (TGF-β-RI) and type II (TGF-β-RII) receptors or kinase deficient TGF-
β type II receptor (TGF-β-RII∆K). To ensure equal amounts of cotransfected
expression vectors under each condition, 1.5 µg of pcDNA3.1 was added to
the cotransfections with each single TGF-β receptor derivative. The day after
transfections some dishes were stimulated with 2 ng per ml of TGF-β for 24 h
(solid bars). The graph depicts means 6 SEM of the collagen promoter activities
relative to the activity of promoter cotransfected with pcDNA3.1 vector that
was arbitrarily set at 1 (all values are normalized for transfection efficiency by
cotransfection with the pSV-β-galactosidase plasmid). The number of
experiments to calculate the mean is shown in parentheses. * indicates statistically
significant results (p , 0.02, Mann–Whitney U test).
Figure 2. Autocrine TGF-β regulates α2 (I) collagen transcription
in human dermal fibroblasts. Human dermal fibroblasts were transiently
cotransfected with 10 µg of α2 (I) collagen promoter/CAT reporter gene
construct and 1.5 µg of the pcDNA3.1 vector (control), or 1.5 µg of pcDNA3.1
carrying wild-type cDNA for the TGF-β type-1 (TGF-β-RI) and type II
(TGF-β-RII) expression vectors. Some of the cotransfected cells were incubated
with anti-TGF-β neutralizing antibody (20 µg per ml), nonspecific IgG (20 µg
per ml), or plasmin (0.1 u per ml). The graph depicts means 6 SEM (from
four experiments) of the collagen promoter activities relative to the activity of
promoter cotransfected with pcDNA3.1 vector that was arbitrarily set at 1.
* indicates statistically significant results (p , 0.02, Mann–Whitney U test).
cDNA for the TGF-β-RI and -RII receptors were cotransfected either
individually or together with the α2 (I) collagen promoter/CAT
reporter gene construct (-772 COL1 A2/CAT) into human dermal
fibroblasts. Overexpression of either receptor type increased (3–4-fold,
p , 0.02) the basal activity of the collagen promoter (Fig 1).
Simultaneous cotransfection of both receptors did not have a signif-
icantly greater effect on the basal collagen promoter activity than
cotransfection with either receptor type alone. Cells cotransfected with
TGF-β receptors were responsive to TGF-β stimulation, and the more
vigorous response was observed in cells cotransfected with both
TGF-β receptors. To test the specificity of the effects generated by
overexpression of TGF-β receptors we employed a kinase deficient
mutant of the TGF-β-RII (TGF-β-RII∆K). Previous studies from
other systems indicated that such mutation exhibits a dominant-
negative effect resulting in blocking of TGF-β responses (Brandt et al,
1993; Yamamoto et al, 1996). Cotransfection of the TGF-β-RII∆K
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with either the wild-type TGF-β-RII or TGF-β-RI significantly
decreased basal activity of the α2 (I) collagen promoter as compared with
cells cotransfected with the wild-type receptor alone and completely
abolished TGF-β stimulation of this promoter (Fig 1).
Previous studies have indicated that human fibroblasts secrete large
amounts of TGF-β (White-Needleman et al, 1990; McWhirter et al,
1994), some of which may be in its active form. Thus, an increase in
the basal activity of the collagen promoter in cells overexpressing TGF-
β receptors may result from the action of such autocrine TGF-β.
Alternatively, overexpression of TGF-β receptors may contribute to
the heteromeric receptor complex formation, resulting in ligand-
independent signaling, a possibility implicated in other experimental
systems (Feng and Derynck, 1996). To resolve this question additional
experiments were performed. First, TGF-β activity was blocked by
adding anti-TGF-β neutralizing antibody (Fig 2). Under this condition
a relatively small (15–20%) but consistent (p , 0.02) decrease of the
collagen promoter activity was observed in cells cotransfected with the
control vector; however, addition of the antibody completely abolished
stimulation of collagen promoter caused by overexpression of TGF-
β-RII or TGFβ-RI. We next compared the effect of plasmin (a known
activator of latent TGF-β) on the collagen promoter activity in cells
cotransfected with control vector or TGF-β-RII. As shown in Fig 2,
addition of plasmin increased collagen promoter activity by about 50%,
indicating the presence of latent TGF-β in dermal fibroblast cultures.
These experiments suggest that α2 (I) collagen transcription is ligand
dependent and that autocrine TGF-β activity contributes significantly
to the constitutive collagen transcription in dermal fibroblasts.
SSc fibroblasts express increased levels of TGF-b type I and
type II receptors Because of the role established for autocrine TGF-
β signaling through type I and type II receptors in controlling collagen
type I transcription in cultured dermal fibroblasts, we examined
receptors in scleroderma fibroblasts. Because SSc fibroblasts overexpress
collagen type I mRNA and protein (LeRoy, 1974; Jimenez et al,
1986), and exhibit elevated activity of the collagen type I promoters
(Kikuchi et al, 1992a; Hitraya and Jimenez, 1996), we considered it
important to examine expression of TGF-β receptors in SSc fibroblasts.
Expression of the TGF-β Type II and Type I receptor mRNA along
with α2 (I) collagen mRNA in four pairs of SSc and normal fibroblasts
was measured (Fig 3a). SSc fibroblasts express increased levels of both
receptor mRNA (2-fold increase, p , 0.02), and correlating increases
in collagen mRNA levels (2.5–3-fold increase, p , 0.02) (Fig 3b).
In addition, we measured TGF-β receptor binding activity by cross-
linking 125I-TGF-β to TGF-β receptors in SSc and normal human
dermal fibroblasts. Note that binding was specific, as determined by a
cold competition assay using 200 3 excess of unlabeled TGF-β (data
not shown). As shown in Fig 4, there is increased binding to TGF-β
receptors in SSc fibroblasts.
In conclusion, SSc fibroblasts exhibit elevated expression of the
TGF-β-RI and -RII receptors that correlates positively with elevated
expression of the collagen α2 (I) gene.
DISCUSSION
TGF-β is currently recognized as a central mediator in various
fibrotic diseases including scleroderma (LeRoy et al, 1989; Border and
Ruoslahti, 1992). The principal effect of TGF-β on mesenchymal cells
is its stimulation of ECM production leading to excessive ECM
deposition. TGF-β has been shown to increase expression of collagen
types I, III, VI, VII, and X, fibronectin matrix glycoproteins, and
proteoglycans (Massague, 1990). Stimulation of ECM production by
TGF-β is further enhanced by its inhibitory effect on matrix degradation
decreasing synthesis of proteases and increasing levels of protease
inhibitors (Massague, 1990). Different cell types, including immune,
endothelial, and mesenchymal cells, may serve as a source of TGF-β
in the fibrotic lesion. Furthermore, sustained production of TGF-β in
the lesion may be maintained by autoinduction (Obberghen-Schilling
et al, 1988). Whereas it is now recognized that constitutively activated
cells in the lesions may also contribute to the disease progression, the
mechanism of this activation is unknown. One possible mechanism
may involve the establishment of an autocrine cytokine loop. Such a
Figure 3. Increased TGF-b receptor expression correlates with the a2 (I)
collagen expression in scleroderma fibroblasts. (a) Total RNA was isolated
from SSc and control fibroblasts and analyzed simultaneously by northern blot.
Blots were sequentially hybridized with probes for TGF-βRI, -RII, COL1 A2,
and GAPDH and quantitated using a phosphorimager. A representative northern
blot is shown in the top panel. Density of the band in normal fibroblasts for
each mRNA was set at 1 (- - - - -). Values from the SSc fibroblasts indicate
band density relative to control. All values were corrected for the loading
differences, as determined by GAPDH mRNA intensity. Quantitative analysis
(mean 6 SEM) of four SSc/normal fibroblast pairs is presented (b). * indicates
statistically significant results (p , 0.02).
loop may be initiated in vivo by exposure to certain cytokines and may
continue to operate in the cell culture conditions. Cytokines known
to induce ECM production, such as TGF-β, IL-4, OSM, or IL-1, are
candidates for such autoinduction, acting separately or in concert.
In this study we have begun to examine the role of autocrine TGF-
β signaling in regulating ECM production in cultured dermal fibroblasts
and a possible contribution of the autocrine TGF-β loop to the SSc
phenotype. Using dermal fibroblasts overexpressing TGF-β-RI and
R-II receptors, we have demonstrated a functional and direct positive
correlation between TGF-β receptor expression levels and collagen
α2 (I) gene transcription both in the presence and in the absence of
added ligand (Fig 1). Significantly, increased collagen transcription was
observed in the absence of serum or other growth factors suggesting
that autocrine TGF-β is constitutively produced and activated by
cultured fibroblasts. This was further confirmed in experiments in
which the action of autocrine TGF-β was blocked by the addition of
anti-TGF-β antibody or enhanced by the addition of plasmin (Fig 2).
These experiments also indicate that levels of TGF-β receptors are the
limiting factor in the autocrine (as well as paracrine) regulation of
collagen type I transcription by TGF-β, because the overexpression of
either type I or type II receptors increased collagen transcription to a
greater extent than addition of an optimal amount of exogenous TGF-
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Figure 4. Display of TGF-b receptors by 125I-labeled TGF-b. Cross-
linking of 125I-TGF-β was performed as described in Materials and Methods.
TGF-β receptors in three pairs of SSc (S) and normal (N) fibroblast are shown.
β to cells with physiologic receptor levels (Fig 1). Addition of the
anti-TGF-β antibody, however, only partially decreased (15–20%)
constitutive transcription of collagen type I, suggesting that cell
mechanisms other than TGF-β are also involved in collagen gene
regulation. These cotransfection experiments presented here establish
the importance of TGF-β receptor expression levels in the regulation
of collagen type I transcription by autocrine TGF-β.
Both type I and II TGF-β receptor mRNA expression levels are
higher in SSc than in healthy fibroblasts (Fig 3), which correlates with
increased binding of TGF-β (Fig 4). This result differs from previous
studies in which TGF-β receptor expression was compared in SSc and
healthy fibroblast using Scatchard analysis (White-Needleman et al,
1990) in which receptor expression level is inferred from the level of
ligand binding. Because of the multiple receptor system for TGF-β,
however, levels of ligand binding do not correlate with signal transduc-
tion due to the high levels of the high affinity but nonsignaling Type
III receptor (reviewed in Attisano et al, 1994). Therefore, Scatchard
analyses are unsuitable for the quantitative analysis of the signal
transducing TGF-β receptor types. We have found that TGF-β
receptors are expressed at higher levels in SSc cells, and, more
importantly, this elevated receptor expression correlates with the
elevated collagen α2 (I) mRNA levels. Taken together with the results
of cotransfection assays (Figs 1, 2), these findings suggest that elevated
expression of TGF-β receptors by SSc fibroblasts in culture may be
responsible for the elevated expression both of collagen type I and of
other ECM proteins also overproduced by cultured SSc fibroblasts. It
is, however, presently unclear why SSc fibroblasts exhibit diminished
responses to exogenous TGF-β (Kikuchi et al, 1992a), despite overexpr-
ession of TGF-β receptors. It is possible that the elevated levels of the
TGF-β receptors render SSc fibroblasts more sensitive to ligand. In
such a case the amount of autocrine TGF-β produced by SSc cells
would be sufficient to maximally activate the signaling pathway,
whereas in normal fibroblasts, with their lower receptor number,
higher amounts of TGF-β are necessary for receptor activation. It has
been previously shown in other experimental systems (Lillien, 1995)
that a 2-fold increase in receptor expression led to at least a 10-fold
decrease in ligand concentration required to induce biologic response.
Other mechanisms such as differences in the post-receptor signaling
pathways between SSc and normal fibroblasts may also be involved.
This important issue will require further studies. It will be of interest
to perform cotransfection experiments directly in SSc and normal
fibroblasts to test the effect of blockage of the TGF-β signaling (e.g.,
by overexpressing dominant-negative TGF-β-RII) on the α2 (I)
collagen promoter activity in both cell types. In our experimental
system, however, we were not able to perform these experiments due
to the significantly low efficiency of transfection in adult dermal
fibroblasts. We envision these experiments in the future studies utilizing
more efficient systems of transfections (e.g., adenoviral vectors, see
Yamamoto et al, 1996). It will also be very important to analyze in situ
the expression of the TGF-β receptors in the SSc lesions. With the
specific reagents now available, such studies are feasible.
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